Literature DB >> 23683536

Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?

Yan Zhang1, Xiao-Yu Li, Yuan Tang, Yong Xu, Wen-Hao Guo, Yan-Chu Li, Xiao-Ke Liu, Chu-Ying Huang, Yong-Sheng Wang, Yu-Quan Wei.   

Abstract

We report the case of an 80-year-old male with relapsed EGFR exon 19 deletion lung adenocarcinoma treated with EGFR-tyrosine kinase inhibitor (TKI), but with poor response and rapid increase of serum neuron specific enolase (NSE). Repeat biopsy identified pathological transformation to small cell lung cancers (SCLC) retaining the same EGFR mutation. This case highlights routine serological testing of NSE may benefit for the lung adenocarcinoma patients resistant to TKIs.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  EGFR mutation; Neuron specific enolase; Non-small cell lung cancer; Small cell lung cancer transformation

Mesh:

Substances:

Year:  2013        PMID: 23683536     DOI: 10.1016/j.lungcan.2013.04.005

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  21 in total

Review 1.  Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review.

Authors:  Yangyang Liu
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

Review 2.  Histologic transformation in lung cancer: when one door shuts, another opens.

Authors:  Yuki Sato; Go Saito; Daichi Fujimoto
Journal:  Ther Adv Med Oncol       Date:  2022-10-14       Impact factor: 5.485

3.  Transformation to small-cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma.

Authors:  Hongyang Lu; Bo Chen; Jing Qin; Fajun Xie; Na Han; Zhiyu Huang
Journal:  Oncol Lett       Date:  2018-02-13       Impact factor: 2.967

Review 4.  Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Authors:  Yi Shao; Dian-Sheng Zhong
Journal:  Int J Clin Oncol       Date:  2017-11-07       Impact factor: 3.402

Review 5.  Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors.

Authors:  Rita Dorantes-Heredia; José Manuel Ruiz-Morales; Fernando Cano-García
Journal:  Transl Lung Cancer Res       Date:  2016-08

6.  Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.

Authors:  Shuxiang Ma; Zhen He; Hongyong Fu; Lili Wang; Xuan Wu; Zhe Zhang; Qiming Wang
Journal:  Transl Lung Cancer Res       Date:  2020-02

Review 7.  Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.

Authors:  J Gao; H-R Li; C Jin; J-H Jiang; J-Y Ding
Journal:  Clin Transl Oncol       Date:  2019-03-12       Impact factor: 3.405

8.  Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.

Authors:  Zhenzhou Yang; Yan Zhang; Rongqing Li; Abulimiti Yisikandaer; Biyong Ren; Jianguo Sun; Jianjun Li; Long Chen; Ren Zhao; Juying Zhang; Xuefeng Xia; Zhongxing Liao; David P Carbone
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

Review 9.  Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments.

Authors:  Antti P Jekunen
Journal:  J Oncol       Date:  2015-01-29       Impact factor: 4.375

10.  Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor.

Authors:  Woo-Jin Kim; Sunmin Kim; Hayoung Choi; Jinsun Chang; Hong-Joon Shin; Cheol-Kyu Park; In-Jae Oh; Kyu-Sik Kim; Young-Chul Kim; Yoo-Duk Choi
Journal:  Thorac Cancer       Date:  2014-12-29       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.